Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at H.C. Wainwright Global Investment Conference

SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
August 07, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
August 06, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update

– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...
July 31, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer

SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
July 30, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Second Quarter 2018 Financial Results

SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
July 02, 2018 16:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 28, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock

SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 27, 2018 16:01 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Commencement of Public Offering of Common Stock

SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 20, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial

– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
June 14, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at JMP Securities Life Sciences Conference

SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...